Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Melanoma
  • Skin Neoplasms

abstract

  • IrAEs are common in patients treated with ipilimumab. In our experience, approximately one-third of ipilimumab-treated patients required systemic corticosteroids, and almost one-third of those required further immune suppression with anti-TNF╬▒ therapy. Practitioners and patients should be prepared to treat irAEs and should understand that such treatment does not affect OS or TTF.

publication date

  • October 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5087335

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.60.8448

PubMed ID

  • 26282644

Additional Document Info

start page

  • 3193

end page

  • 8

volume

  • 33

number

  • 28